Combining Best of Both Worlds for Cancer Modeling

Treatment options for many types of cancers remain limited, due partly to the in vitro tools used to model cancers and that results from animal studies do not always translate well to human disease. These shortcomings point to a clear need for a better, patient-specific model. Researchers suggest bioengineered microscale organotypic models can address this need. They discuss the advantages and capabilities of this technique, as well as its challenges, in the journal APL Bioengineering.